Digital Therapeutics (DTx)

DTx represent an emerging field of software-driven, evidence-based products intended to “prevent, manage, or treat a medical disease or disorder.” Cybersecurity is a concern for DTx, whether they are being evaluated through clinical research or are aiming at market release.

Trialbee, the leading enrollment performance company, and Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced a strategic partnership to accelerate patient enrollment, optimize patient engagement, and reduce site burden for clinical trials globally.

Castor is supporting the next generation of digital therapeutics that can improve patient lives with disease-modifying potential.

This playbook is a tool for sponsors and CROs who want to leverage DCT technology to support remote interactions in their clinical studies.